Field Medical has announced the publication of 12-month results from its first-in-human Field PULSE trial in JACC: Clinical Electrophysiology alongside their simultaneous presentation as a late-breaking clinical trial at HRX Live 2026 (18–20 September, Atlanta, USA).
Field Medical notes in a press release that it developed the FieldForce pulsed field ablation (PFA) system around a high-voltage focal PFA architecture—designed first for the ventricle, where depth, stability and control are among the most difficult ablation-related challenges. Field PULSE extends that work into the atrium and evaluates a sub-second, point-by-point workflow that the company terms ‘instantaneous ablation’.
In the present study, this approach was associated with procedural efficiency, durable pulmonary vein isolation (PVI), and flexibility beyond the pulmonary veins, without the need for prolonged catheter stability.
“Field PULSE demonstrates the feasibility of truly instantaneous focal PFA,” said co-principal investigator and lead author Vivek Reddy (Mount Sinai Health System, New York, USA). “Delivering the full application in less than 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation. The procedural efficiency, safety and pulmonary vein durability observed with the optimised waveform support continued clinical development of this approach.”
Key findings from the trial are as follows:
- Procedural efficiency with sub-second focal PFA, demonstrated via a 13-minute median elapsed PVI ablation time, with a fastest time of 7.7 minutes
- Durable PVI with the optimised waveform, as per a 94.2% rate of per-vein durability, reflecting progressive improvement with waveform evolution
- Some 49% of patients received non-PV ablation for additional atrial targets, indicating flexible focal ablation was successfully achieved
- No primary safety events were observed
- A rate of 80% freedom from atrial arrhythmias at 12 months with the optimised waveform
This latest publication builds on Field Medical’s peer-reviewed clinical work in ventricular tachycardia. Six-month outcomes from the company’s first-in-human VCAS trial were published in Circulation last year. Field PULSE now adds first-in-human, peer-reviewed atrial data evaluating the same high-voltage focal PFA architecture through a distinct focal workflow in a different cardiac substrate, according to Field Medical’s recent press release.
“We designed FieldForce to solve some of the hardest problems in focal cardiac ablation, beginning in the ventricle,” said Mark Turco, the company’s president and chief executive officer (CEO). “Field PULSE demonstrates that the same high-voltage focal PFA architecture can support an instantaneous ablation workflow in the atrium. This growing body of evidence reinforces the range of the platform: depth and focal control in the ventricle, speed and precision in the atrium, and the versatility to address very different cardiac substrates through a familiar point-by-point approach. These results add important clinical evidence as we continue to advance our differentiated PFA platform.”
